Delivery Order SPE2DB20D1109-SPE2DB25FP84Q
- Not listed
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,823.64 for 50-unit vials of Xeomin, a botulinum toxin injection used for therapeutic and cosmetic applications. This firm fixed-price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a non-competitive set-aside award issued under the company's larger indefinite delivery contract. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $12,851.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The company...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $27,937 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a non-competitive, direct fulfillment order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 delivery order for Xeomin 100 Unit Vials, a botulinum toxin product used for medical purposes. This competitive award, issued on August 25, 2025, carries an ultimate completion date of September 16, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under the company's...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP84QDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,793.70 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic purposes. Issued on September 26, 2025, with an ultimate completion date of October 20, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside contract. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle valued through December 2026 that serves as a comprehensive global pharmaceutical support mechanism. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs and the Defense Health Agency worldwide. The company's extensive portfolio of federal medical procurement demonstrates its capability to meet demanding supply chain requirements across multiple therapeutic domains for the Department of Defense and related federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 9/26/25 |